2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1111

Erosive Evolution in Hand Osteoarthritis Is Associated with Incident Joint Tenderness Independent of MRI-Defined Bone Marrow Lesions and Synovitis
Abstract Number: 1389

Erythrocyte Sedimentation Rate Is a Predictor of Renal and Overall Systemic Lupus Erythematosus Disease Activity
Abstract Number: 2455

Establishment of Standardized International Units for IgG Anti-β₂glycoprotein Antibody Measurement
Abstract Number: 678

Estrogen Modulation of ZAS3 Is Mediated Through Estrogen Receptor α: An Underlying Mechanism of Gender-Bias in Systemic Lupus Erythematosus?
Abstract Number: 1451

Estrogen Receptor Alpha Deficiency Protects Against Cognitive Defects in Murine Lupus
Abstract Number: 1453

Estrogen Receptor Alpha Impacts Th17 Expansion in Murine Lupus
Abstract Number: 664

Estrogen Upregulates Interleukin-21 Production of Clusters of Differentiation 4 Positive T Lymphocytes in Patients with Systemic Lupus Erythematosus
Abstract Number: 480

Etanercept Induces A Significant Decrease of Oxidative Stress and Osteoprotegerin Compared with Sdmard in Patients with Rheumatoid Arthritis
Abstract Number: 1420

Ethnicity and B Cell Depletion Therapy in Systemic Lupus Erythematosus
Abstract Number: 188

Etiology of Uveitis: A Hospital-Based Study in a Referral Centre
Abstract Number: 163

Evaluating Allopurinol Therapy and Serum Uric Acid Levels in Medicare Beneficiaries with Gout
Abstract Number: 138

Evaluating Appropriate Use of Prophylactic Colchicine and Urate Lowering Therapy in Gout
Abstract Number: 278

Evaluating Cardiovascular Risk Factors of Impaired Glucose Tolerance, Diabetes Mellitus, and Metabolic Syndrome in a Primarily Latino Population with Pediatric Rheumatic Diseases Associated with Vasculitis
Abstract Number: 1832

Evaluating the Cost-Effectiveness of Personalized Treatment with Adalimumab Using Serum Drug Levels in Rheumatoid Arthritis Patients
Abstract Number: 1928

Evaluating the Therapeutic Effects of B Cell Depletion Therapy with Rituximab in a Longitudinal Cohort of Mixed Connective Tissue Disease Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].